Beyond COVID-19: DO MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies?

Since 2019, a new coronavirus infection (COVID-19) due to an agent called SARS-CoV-2 spread rapidly worldwide. Patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMO-SD) are often treated with immunosuppressants. Beyond their effect on the risk of COVID-19 infection,...

Descripción completa

Detalles Bibliográficos
Autores principales: Maillart, Elisabeth, Papeix, Caroline, Lubetzki, Catherine, Roux, Thomas, Pourcher, Valérie, Louapre, Céline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7468278/
https://www.ncbi.nlm.nih.gov/pubmed/32916509
http://dx.doi.org/10.1016/j.msard.2020.102482

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7468278/
https://www.ncbi.nlm.nih.gov/pubmed/32916509
http://dx.doi.org/10.1016/j.msard.2020.102482

Ejemplares similares